Quick Answer
Lyra Therapeutics, Inc. reported R&D Expense of $18.41 million for fiscal year 2025.
Lyra Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $18.41M | -57.9% |
| 2024 | $43.77M | -8.9% |
| 2023 | $48.03M | +23.8% |
| 2022 | $38.80M | +30.7% |
| 2021 | $29.69M | +137.1% |
| 2020 | $12.52M | +4.1% |
| 2019 | $12.03M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.05M | -31.4% | -20.8% |
| June 30, 2025 | $5.11M | -61.5% | +4.8% |
| March 31, 2025 | $4.88M | -73.3% | -17.4% |
| September 30, 2024 | $5.90M | -52.3% | -55.5% |
| June 30, 2024 | $13.26M | +22.8% | -27.3% |
| March 31, 2024 | $18.24M | +44.8% | +47.5% |
| September 30, 2023 | $12.37M | +23.1% | +14.5% |
| June 30, 2023 | $10.80M | +0.1% | -14.3% |
- Lyra Therapeutics, Inc. showed a decrease of -57.9% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Lyra Therapeutics, Inc.’s r&d expense has grown by 53.0% (from $12.03 million to $18.41 million).
- The most recent figure is from Lyra Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: